DMSCAREPHARMA Sulfadoxine-pyrimethamine +Dihydroartemisinin tablets

Sulfadoxine-pyrimethamine+Dihydroartemisin tablets
Click to add this item to cart.

Product Description

Product Name:

Sulfadoxine-pyrimethamine+Dihydroartemisinin tablets

Contains:

Sulfadoxine /pyrimethamine 157 mg tablet
Dihydroartemisinin 600 mg tablet

Package:

Sulfadoxine /pyrimethamine 157 mg 3 tablets
Dihydroartemisinin 600 mg 6 tablets

Indication

  • Seasonal Malaria Chemoprevention (SMC) for children most at risk of severe malaria in areas with seasonal malaria transmission

Dosing:

  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles during peak malaria transmission season

Dihydroartemisinin (also known as dihydroqinghaosuartenimol or DHA) is a drug used to treat malaria. Dihydroartemisinin is the active metabolite of all artemisinin compounds (artemisinin, artesunate, artemether, etc.) and is also available as a drug in itself. It is a semi-synthetic derivative of artemisinin and is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs. It is sold commercially in combination with piperaquine and has been shown to be equivalent to artemether/lumefantrine.

Sulfadoxine/pyrimethamine, sold under the brand name Fansidar, is a combination medication used to treat malaria.It contains sulfadoxine (a sulfonamide) and pyrimethamine (an antiprotozoal). For the treatment of malaria it is typically used along with other antimalarial medication such as artesunate. In areas of Africa with moderate to high rates of malaria, three doses are recommended during the second and third trimester of pregnancy.

Side effects include diarrhea, rash, itchiness, headache, and hair lossRarely a severe allergic reaction or rash such as toxic epidermal necrolysis, may occur. It is not generally recommended in people with a sulfonamide allergy or significant liver or kidney disease. It works by blocking malaria’s ability to use folinic acid.

Sulfadoxine/pyrimethamine was initially approved for medical use in the United States in 1981. It is on the World Health Organization’s List of Essential Medicines.It is not commercially available in the United States.